No treatments have yet been found to halt or reverse the progress of Alzheimer's disease. Now, a protein discovered 25 years ago in the research lab of Paul Lombroso, MD, the Elizabeth Mears and House Jameson Professor in the Child Study Center at Yale, may offer new hope.
Scientists have for the first time identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma. Researchers have implicated a mutant form of a protein called myocilin as a possible root cause of this increased eye pressure.
Scientists at Washington University School of Medicine in St. Louis have identified variations in a gene that double a person’s risk of developing Alzheimer’s disease later in life. Their research is published online in the journal Nature.
Researchers found that they could reduce beta-amyloid when their drug was added to cultured brain cells and when injected directly into the brains of mice designed to show features of Alzheimer’s disease.
December 6, 2013
Donate to Cure Brain and Eye Diseases
Help end Alzheimer's, Macular Degeneration, and Glaucoma